Dave Kappos Speaks at the Hudson Institute’s Webinar on Standard‑Essential Patents
February 04, 2022
On February 2, 2022, Cravath partner David J. Kappos participated in a webinar hosted by the Hudson Institute. The session, entitled “The New Policy Statement on Standard‑Essential Patents: A Move in the Wrong Direction?,” examined the Antitrust Division of the U.S. Department of Justice’s proposed policy statement on patents essential to practice industry standards and its potential impact on innovation and the United States’ ability to compete for global technological leadership.
Related Practices & Industries
Speakers
- Photo
-
-
J.D., 1990, University of California, Berkeley, School of Law
-
B.S., 1983, University of California, Davissumma cum laude
- New York
- California
- District of Columbia
Education
Admitted In
Related News & Insights
Deals & Cases
December 27, 2021
FactSet’s $1.9 Billion Acquisition of S&P Global’s CUSIP Global Services
On December 27, 2021, FactSet, a global provider of integrated financial information and analytical applications, announced that it has entered into a definitive agreement to acquire CUSIP Global Services, an operator of market standard security identifiers, from S&P Global for $1.925 billion in cash. Cravath is representing FactSet in connection with the transaction.
Deals & Cases
November 29, 2021
Elsevier’s Acquisition of Osmosis
On November 29, 2021, Elsevier, a global leader in research publishing and information analytics and part of RELX, announced that it has acquired Osmosis, a U.S.‑based visual learning education platform for millions of current and future healthcare professionals and their patients. RELX is a global provider of information‑based analytics and decision tools for professional and business customers. Cravath is representing RELX in connection with the transaction.
Deals & Cases
November 29, 2021
Vaxxinity, Inc.’s Initial Public Offering
Cravath represented Vaxxinity, Inc. in connection with its initial public offering. Vaxxinity is a U.S.‑based global biotechnology company pioneering a new class of immunotherapeutic vaccines to democratize health. Shares began trading on November 11, 2021 on The Nasdaq Global Market.
Deals & Cases
November 15, 2021
CyrusOne’s $15 Billion Acquisition by KKR and Global Infrastructure Partners
On November 15, 2021, CyrusOne Inc. (“CyrusOne”), a premier global data center REIT, KKR, a leading investment firm, and Global Infrastructure Partners, a leading infrastructure investor, announced a definitive agreement pursuant to which KKR and GIP will acquire all outstanding shares of common stock of CyrusOne for $90.50 per share in an all‑cash transaction valued at approximately $15 billion, including the assumption of debt. Upon completion of the transaction, CyrusOne will be a privately held company wholly owned by KKR and GIP and CyrusOne’s common stock will no longer be listed on any public market. Cravath is representing CyrusOne in connection with the transaction.
